Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
HIF-2 alpha/EPAS1 Antibody (ep190b), Alexa Fluor™ 750, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NB100132AF750
Description
HIF-2 alpha/EPAS1 Monoclonal specifically detects HIF-2 alpha/EPAS1 in Human, Mouse, Rat, Bovine, Hamster samples. It is validated for Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Knockdown Validated.Specifications
HIF-2 alpha/EPAS1 | |
Monoclonal | |
Alexa Fluor 750 | |
50 mM sodium borate with 0.05% sodium azide | |
EPAS1 | |
The immunogen recognized by this HIF-2 alpha/EPAS1 Antibody (ep190b) maps to a region between amino acids 535-631. [UniProt# Q99814] | |
0.1 mL | |
Primary | |
This HIF-2 alpha/EPAS1 Antibody (ep190b) is specific for HIF-2 alpha/EPAS1, and does not cross-react with HIF-1 alpha. | |
Store at 4°C in the dark. |
Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), KnockDown | |
ep190b | |
Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Knockdown Validated | |
Basic-helix-loop-helix-PAS protein MOP2, BHLHE73, Class E basic helix-loop-helix protein 73, ECYT4, endothelial PAS domain protein 1, endothelial PAS domain-containing protein 1, EPAS1, EPAS-1, HIF-1-alpha-like factor, HIF-1alpha-like factor, HIF-2 alpha, | |
Mouse | |
Protein G purified | |
Angiogenesis, Apoptosis, Cancer, Cancer Stem Cells, Chromatin Research, Embryonic Stem Cell Markers, HIF Target Genes, Hypoxia, Lipid and Metabolism, Transcription Factors and Regulators | |
2034.0 | |
Human, Mouse, Rat, Bovine, Hamster | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction